Navigation Links
Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device
Date:3/8/2011

y vascular closure experience.  The Mynx device utilizes an extravascular water-soluble polyethylene glycol (PEG) sealant that is gently deployed at the surface of the femoral artery.   Following deployment, the sealant immediately expands sealing the common femoral artery and tissue tract.  The sealant dissolves within 30 days, leaving nothing behind but a healed artery.  The Mynx received its first FDA approval in May 2007, has been used in over 750,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.  For more information, visit our website at www.accessclosure.com.

*This study was an independently run physician-initiated study.   AccessClosure, Inc. had no input into data collection, analysis or presentation. The study was funded in part by a scientific research grant from AccessClosure, Inc.


'/>"/>
SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Georgia Health Sciences University Clinical Study Shows RyMed InVision-PlusĀ® IV Connector Significantly Decreased Central Venous Catheter Occlusions in Oncology Patients
2. Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year
3. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
4. Structured Diabetes Management can Significantly Improve Overall Glycemic Control and Reduce HbA1c Values in Non-insulin Treated Type 2 Diabetes
5. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
6. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
7. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
8. STALLERGENES : Significant Growth : Q3 2010 + 10% and +12% Over the First 9 Months / Shionogi Partnership: First EUR24 Million Instalment
9. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
10. Cord Blood America Says Outreach Program to OB/GYN Nurses, Insurance Case Workers, Paying Significant Dividends
11. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Reiterates $3.00 per Share Proposal is Best and Final ... Company,(NYSE: LLY ) today reaffirmed that its $3.00 ... SGXP ) represents its best and final offer,for the ... two,companies announced the signing of a definitive merger agreement, ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company focused ... in the areas of women,s health and,cancer, announced today ... presenting at the BMO Capital Markets 2008 Focus on ... begin at 2:15 PM,ET on Tuesday, August 5, 2008 ...
... to Monitor Activity of New ... Class of Potent Antiretroviral Drugs, SOUTH SAN ... ) today announced the launch of its,PhenoSense(R) Integrase assay, built ... susceptibility of,HIV to a new and potent class of integrase ...
Cached Biology Technology:Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 3Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 4Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 5
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... scientist, has just solved the structure of the first mammalian ... and certain cancers. His work is being published today ... Molecular Cell. Gewirths study confirms his 2001 ... same family as the better known HSP90 proteins. As ...
... Spring Harbor, NY Gregory J. Hannon, Ph.D., ... Hughes Medical Institute (HHMI) investigator, along with two ... the Memorial Sloan-Kettering Cancer Centers (MSKCC) 2007 Paul ... named after Paul A. Marks, Ph.D., President Emeritus ...
... researchers have shown that nanodiamonds -- much like the ... diamond but on a much smaller scale -- are ... the negative effects associated with current drug delivery agents. ... Letters, is the first to demonstrate the use of ...
Cached Biology News:First high-res 3D structures of mammalian HSP90 protein solved 2First high-res 3D structures of mammalian HSP90 protein solved 3Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2Nanoengineers mine tiny diamonds for drug delivery 2Nanoengineers mine tiny diamonds for drug delivery 3Nanoengineers mine tiny diamonds for drug delivery 4
Request Info...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Polyclonal Antibody to PRG3...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Biology Products: